Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 21, 2026, 4:16 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1441–1464 of 3,924 matching trials from the live ClinicalTrials.gov search.
Conditions
Cancer, Cancer Diagnosis, Early Detection of Cancer, Breast Cancer, Lung Cancer, Colon Cancer, GI Cancer, Gynecologic Cancer, Ovarian Cancer, Endometrial Cancer, CNS Cancer, Hematologic Cancer
Interventions
Not listed
Lead sponsor
Avera McKennan Hospital & University Health Center
Other
Eligibility
18 Years and older
Enrollment
25,000 participants
Timeline
2021 – 2026
U.S. locations
6
States / cities
Marshall, Minnesota • Aberdeen, South Dakota • Mitchell, South Dakota + 3 more
Conditions
Tuberous Sclerosis Complex
Interventions
everolimus
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years to 65 Years
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
14
States / cities
Phoenix, Arizona • Los Angeles, California • Oakland, California + 11 more
Conditions
Brain and Central Nervous System Tumors, Metastatic Cancer
Interventions
iodine I 131 monoclonal antibody 81C6
Radiation
Lead sponsor
Duke University
Other
Eligibility
3 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2010
U.S. locations
1
States / cities
Durham, North Carolina
Completed Not applicable Interventional Accepts healthy volunteers

Virtual Reality-Based Exercise in Cancer Patients

NCT02165163
Conditions
Distorted; Balance, Motor Deficit
Interventions
Balance Training
Other
Lead sponsor
University of Arizona
Other
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Tucson, Arizona
Conditions
Brain Cancer, Brain Neoplasm, Glioma, Glioblastoma, Gliosarcoma, Malignant Brain Tumor, Neoplasm, Neuroepithelial, Neuroectodermal Tumors, Neoplasm by Histologic Type, Neoplasm, Nerve Tissue, Nervous System Diseases
Interventions
DNX-2401, pembrolizumab
Biological
Lead sponsor
DNAtrix, Inc.
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
14
States / cities
Little Rock, Arkansas • Los Angeles, California • Chicago, Illinois + 10 more
Conditions
Mesothelioma, Non Small Cell Lung Cancer, Malignant Peripheral Nerve Sheath Tumors, Solid Tumor, Pancreatic Adenocarcinoma, Advanced Solid Tumor
Interventions
MRTX1719
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
24
States / cities
Phoenix, Arizona • Lone Tree, Colorado • Jacksonville, Florida + 20 more
Conditions
Brain Tumor, Glioblastoma Multiforme
Interventions
Not listed
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Miami, Florida
Conditions
Cancer, Acute Lymphoblastic Leukemia, Lymphoma, Sarcoma, Acute Myelogenous Leukemia, Brain Tumors, Germ Cell Tumor
Interventions
Promoting Resilience In Stress Management (PRISM)
Behavioral
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
13 Years to 25 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Conditions
HER2-positive Metastatic Breast Cancer, Central Nervous System Metastases
Interventions
ATEZOLIZUMAB, PERTUZUMAB, TRASTUZUMAB
Drug
Lead sponsor
Nancy Lin, MD
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
2
States / cities
Chicago, Illinois • Boston, Massachusetts
Conditions
Brain Neoplasms, Central Nervous System Neoplasms
Interventions
TPI287, Bevacizumab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Houston, Texas
Conditions
Brain and Central Nervous System Tumors
Interventions
lymphokine-activated killer cells, polifeprosan 20 with carmustine implant
Biological · Drug
Lead sponsor
Lisata Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Newport Beach, California
Conditions
Generalized Myasthenia Gravis
Interventions
Batoclimab 680 mg SC weekly, Batoclimab 340 mg SC weekly, Matching Placebo SC, Batoclimab 340 mg SC bi-weekly
Drug
Lead sponsor
Immunovant Sciences GmbH
Industry
Eligibility
18 Years and older
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
30
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Carlsbad, California + 27 more
Conditions
Neurofibromatosis Type 1
Interventions
Not listed
Lead sponsor
University of Utah
Other
Eligibility
6 Years to 9 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
ALK-Positive Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation, Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, EBV-Positive Mucocutaneous Ulcer, HHV8-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma, Not Otherwise Specified, Intravascular Large B-Cell Lymphoma, Large B-Cell Lymphoma With 11q Aberration, Large B-Cell Lymphoma With IRF4 Rearrangement, Plasmablastic Lymphoma, Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System, Primary Effusion Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Burkitt Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Gray-Zone Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Recurrent Lymphomatoid Granulomatosis, Recurrent Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, Recurrent Primary Mediastinal Large B-Cell Lymphoma, Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Burkitt Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Gray-Zone Lymphoma, Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Refractory Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, Refractory Primary Mediastinal Large B-Cell Lymphoma, Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
Interventions
Nivolumab, Varlilumab
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
33
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Jacksonville, Florida + 24 more
Conditions
Breast Cancer Survivors
Interventions
Active taVNS, Sham taVNS
Device
Lead sponsor
Florida State University
Other
Eligibility
18 Years to 79 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Tallahassee, Florida
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Pilot Study to Evaluate Efficacy and Safety of Clevidipine in Neurosurgical Patients

NCT00952081
Conditions
Hypertension, Brain Tumor, Epilepsy
Interventions
Clevidipine
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
21 Years and older
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
New York, New York
Conditions
Retrospective Study, Glioma, Brain Neoplasms
Interventions
18F(FET)PET
Diagnostic Test
Lead sponsor
Telix Pharmaceuticals (Innovations) Pty Limited
Industry
Eligibility
Not listed
Enrollment
253 participants
Timeline
2025 – 2026
U.S. locations
1
States / cities
San Francisco, California
Conditions
Recurrent Glioblastoma Multiforme
Interventions
131-I-chTNT-1/B MAB
Drug
Lead sponsor
Peregrine Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
4
States / cities
Phoenix, Arizona • Cleveland, Ohio • Philadelphia, Pennsylvania + 1 more
Conditions
Brain Tumor
Interventions
Sotorasib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 3 more
Conditions
Tuberous Sclerosis
Interventions
JASPER
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
6 Months to 40 Months
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
2
States / cities
Los Angeles, California • Boston, Massachusetts
Conditions
Cancer of Head and Neck, Pain, Face, Pain, Neck
Interventions
ExAblate Neuro
Device
Lead sponsor
Jeff Elias, MD
Other
Eligibility
18 Years to 75 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Charlottesville, Virginia
Conditions
Glioblastoma Multiforme
Interventions
Pembrolizumab, Stereotactic Radiation Therapy, Surgical Resection
Drug · Radiation · Procedure
Lead sponsor
Chirag G. Patil
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Brain Neoplasms
Interventions
Whole Brain Irradiation, Partial Brain Irradiation, Neuropsychological Testing, Quality of Life Questionnaire, Magnetic Resonance Imaging (MRI) Assessments
Radiation · Behavioral · Device
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2014
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Chemotherapy-induced Peripheral Neuropathy
Interventions
Arm 1: Investigational INF, Arm 2: standardized muscle stretching and strength
Other
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years and older · Female only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Loma Linda, California